Discover new treatments and vaccines that could revolutionize the fight against HIV

The fight against HIV has evolved significantly over the decades, with transformative medical advances that promise to change the course of this global epidemic. New treatments and vaccines are emerging as great hope not only for improving the quality of life of people living with HIV, but also to open up new possibilities for preventing and controlling the virus. In this article, we will explore how these innovations are shaping the future of medicine and offering a light for millions of individuals around the world.

An overview of HIV/AIDS in Brazil

O Brazil has faced the epidemic of HIV / AIDS since the 1980s, when the first cases were recorded in the country. Since then, great progress has been made in combating the virus, including expanding access to treatments and raising awareness. In 2023, approximately 51.000 new cases of HIV were recorded, with an incidence rate of 0,24 per 1.000 uninfected people. The prevalence among adults aged 15 to 49 is 0,6%, which represents about 1 million people living with HIV in Brazil.

Important milestones in the fight against HIV / AIDS include the creation of the “Red December” campaign in 2017, which aims to raise awareness among the population about the prevention, diagnosis and treatment of HIV / AIDS. Furthermore, access to antiretroviral therapy (ART) has increased significantly over the years. In 2010, 7,7 million people were receiving treatment, a number that grew to 30,7 million by 2023. This increase in access to medicines has been crucial in improving the quality of life of people living with HIV and in controlling the spread of the virus.

The success of antiretroviral therapies is also reflected in treatment adherence. By 2023, 82% of people living with HIV in Brazil were on ART, which represents an important advance in the response to the epidemic. These treatments help to suppress the viral load, keeping it at undetectable levels and increasing the CD4 cell count, essential for the immune system. The continuous evolution of treatments and the focus on public health policies have been fundamental to the progress achieved in the fight against HIV / AIDS in Brazil.

O Unified Health System (SUS) has played a crucial role in the fight against HIV / AIDS in Brazil, offering free treatment to all people living with HIV who require antiretroviral therapy (ART). Since 1996, the SUS distributes antiretroviral drugs free of charge, ensuring that millions of Brazilians have access to the treatment they need to control the infection and improve their quality of life. Currently, the SUS offers 22 medicines in 38 pharmaceutical presentations, ensuring a wide range of therapeutic options to meet the individual needs of patients.

Furthermore, the Basic Health Units (UBS) offer rapid tests for Sexually Transmitted Infections (STIs) such as HIV, syphilis, hepatitis B and hepatitis C, as well as HPV. These tests are performed free of charge by SUS, ensuring ease of access and complete anonymity for users. This is essential for the early detection and timely treatment of these infections, especially in risky situations, such as when a condom tears during sexual intercourse. Carrying out these rapid tests at UBSs provides a practical and bureaucracy-free alternative, promoting public health and preventing future complications.

Difference between HIV and AIDS

The fundamental difference between HIV e AIDS is in the nature of the virus and the disease caused by it. The HIV (Human Immunodeficiency Virus) is the virus that causes the infection. It attacks the immune system, specifically CD4 cells, which are crucial to the body's defense against infections. The HIV spreads primarily through contact with bodily fluids such as blood, semen, vaginal fluids, and breast milk. Infection with HIV can be controlled through antiretroviral therapies (ARVs), which help keep the viral load low and the immune system functional.

A AIDS (Acquired Immune Deficiency Syndrome) is the condition that occurs when the HIV is not treated and the immune system is severely damaged. This advanced stage of the infection HIV is characterized by a significant decrease in CD4 cells, leaving the body vulnerable to opportunistic infections and certain types of cancer that would not affect a healthy immune system. AIDS is not a separate disease, but a set of symptoms and infections that occur due to immunodeficiency caused by HIV untreated.

Therefore, a person can be infected by HIV without developing AIDS if the virus is adequately controlled with treatment. With advances in antiretroviral drugs, many people living with HIV never develop AIDS, and can lead a long and healthy life. It is crucial to diagnose and start treatment as early as possible to prevent progression of the disease. HIV for AIDS and improve the quality of life of patients.

What is life like for an HIV patient today?

The life of a patient with HIV today is significantly better than in past decades, thanks to advances in medicine and increased awareness of the disease. One of the main factors that positively influence the lives of people living with HIV is access to antiretroviral therapies (ARVs). These medications allow individuals to maintain their viral load at undetectable levels, which not only improves overall health but also reduces the risk of transmitting the virus to virtually zero. Adherence to treatment is crucial, and fortunately, many patients have access to regular medical care that makes it easier to monitor and adjust therapies as needed.

In addition to medical advances, society has become increasingly aware and open about HIV, reducing the stigma and discrimination faced by those living with the virus. Educational campaigns and support initiatives have helped to demystify the disease and promote greater social inclusion. However, stigma can still be a significant challenge for many, affecting their mental health and emotional well-being. It is essential that patients have access to psychological and social support networks to help them cope with these issues.

Another crucial point is the quality of life and life expectancy of people living with HIV. With proper treatment, many people with HIV can live as long as those who do not have the virus, maintaining an active and healthy professional and personal life. However, it is important to consider issues related to aging with HIV, such as a greater propensity for comorbidities and the need for constant medical monitoring. Effective public policies and continued access to health services are vital to ensure that these people can age with dignity and quality of life.

PrEP, Doxi PEP and other forms of prevention

Prevention strategies HIV have evolved significantly in recent years, providing new tools to reduce the risk of infection. Key approaches include PrEP (Pre-Exposure Prophylaxis), a highly effective preventive method for people who are at higher risk of contracting the HIV, and Doxi PEP (Doxycycline Post-Exposure Prophylaxis), which has shown promise in recent studies. In this topic, we will explore in detail these innovative strategies and how they can transform the prevention of HIV.

PreP

A PreP (Pre-Exposure Prophylaxis) is a preventive strategy used to avoid infection by HIV. This approach involves daily use of a combination of antiretrovirals, usually tenofovir and emtricitabine, which help block the virus from replicating in the body. When taken consistently, PreP can significantly reduce the risk of infection by HIV, especially in people who are at higher risk, such as those with partners living with HIV or who have high-risk sexual practices. The effectiveness of PreP is maximized when combined with other prevention measures, such as the use of condoms.

In addition to its effectiveness, the PreP is known for its ease of use, being administered in the form of daily tablets. This preventive method has been widely adopted and promoted by public health programs around the world due to its proven efficacy and safety. Adherence to the regimen PreP is crucial to ensure its effectiveness, and therefore it is important that users maintain regular follow-up with health professionals to monitor possible side effects and carry out periodic health check-ups. HIV.

A PrEP is offered free of charge by SUS in Brazil. O SUS provides the combination of antiretrovirals tenofovir and emtricitabine through its health posts and reference centers throughout the country. In addition to providing the medicines, the SUS also carries out regular medical monitoring, including periodic examinations HIV and counseling, to ensure effectiveness and adherence to treatment, in addition to monitoring possible side effects.

Injectable PrEP

A Injectable PrEP is an alternative to Oral PreP, offering a practical option for those who prefer not to take daily pills. This form of prophylaxis involves administering antiretroviral injections at regular intervals, usually every one to two months. The drugs used in Injectable PrEP also act by blocking the replication of HIV, providing effective protection against infection. The Injectable PrEP It is especially useful for people who may have difficulty maintaining adherence to their daily pill regimen.

In addition to the convenience of less frequent administration, the Injectable PrEP maintains effectiveness in preventing HIV, providing a viable alternative for many users. As the Oral PreP, Injectable PrEP should be combined with other prevention practices, such as condom use, to maximize its effectiveness. Regular medical follow-up is essential to monitor the response to treatment and adjust doses as necessary, ensuring that protection against HIV is maintained continuously and securely.

DoxiPEP

A DoxiPEP (Post-Exposure Prophylaxis with Doxycycline) is a preventive strategy used after possible exposure to HIV. This method involves administering a combination of antiretrovirals, including doxycycline and emtricitabine/tenofovir, within a short period after exposure. The DoxiPEP works by blocking the replication of HIV before it can establish itself in the body, offering effective protection when initiated quickly after exposure. This regimen is particularly useful in situations of accidental or unexpected exposure to HIV.

The administration of DoxiPEP generally follows a regimen of 2 to 3 doses within 72 hours of exposure, as directed by a physician. The effectiveness of this preventive method depends on how quickly it is started after exposure, as well as adherence to the prescribed regimen. DoxiPEP complements other forms of prevention, offering an additional layer of protection in emergencies. As with all disease prevention strategies, HIV, medical follow-up is essential to monitor effectiveness and adjust treatment as necessary.

A DoxiPEP is offered by SUS as an emergency measure to prevent infection by HIV after possible exposure. The post-exposure prophylaxis regimen includes administration of doxycycline and emtricitabine/tenofovir, available at reference centers and health units in the SUS. The effectiveness of DoxiPEP depends on how quickly it is initiated after exposure, and the SUS ensures that patients receive adequate guidance to adhere to the prescribed regimen.

Current Antiretroviral Therapies (ARVs)

As Antiretroviral Therapies (ARVs) are essential in the fight against HIV, as they help control the virus and prevent its progression to AIDS. These therapies use a combination of drugs that act at different stages of the animal's life cycle. HIV, preventing the virus from multiplying and damaging the immune system. The main goal of ARVs is to keep the viral load at undetectable levels, which not only improves the patient's overall health but also significantly reduces the risk of transmitting the virus to others.

The regime of ARVs typically includes a combination of three or more drugs, chosen based on the patient's individual health profile and the resistance of the virus. In addition to reducing viral load, ARVs increase the count of CD4 cells, immune system cells that are attacked by HIV. Maintaining a high CD4 cell count is crucial for immune function and preventing opportunistic infections and other diseases. With advances in medicine, ARV treatments have become more effective, safer and easier to administer, providing a better quality of life for people living with HIV.

Dolutegravir (DTG)

Dolutegravir is an integrase inhibitor, a type of drug that prevents HIV to integrate into the DNA of host cells. By blocking this crucial step in the virus replication cycle, Dolutegravir helps maintain viral load at undetectable levels. This medication is generally well tolerated by patients and has the advantage of being administered once a day, which makes it easier to adhere to treatment. Dolutegravir It is often used in combination with other antiretrovirals to increase the effectiveness of treatment and minimize resistance to the virus.

Medicines that contain Dolutegravir are recommended for both people who are starting treatment and those who already have experience with other antiretroviral therapies. In addition to their effectiveness in controlling viral load, Dolutegravir It also has a good safety profile and few side effects. It is particularly useful for pregnant women as it offers a safe and effective treatment during pregnancy.

Tenofovir (TDF)

tenofovir is a nucleotide reverse transcriptase inhibitor (NRTI), which interferes with the ability of HIV to copy its genetic material and replicate itself. By preventing the virus from replicating, tenofovir helps keep viral load low and preserve immune function. This medication is often used in combination with other ARVs and is a popular choice due to its efficacy and safety profile. tenofovir It is administered once a day, which facilitates adherence to treatment, and is used for both treatment and prevention of HIV.

In addition to its use in the treatment of HIV, tenofovir It is also a key component in pre-exposure prophylaxis (PrEP), a prevention method that can significantly reduce the risk of HIV infection. HIV in uninfected people. tenofovir has been shown to be effective and safe, with generally mild and manageable side effects.

Darunavir (DRV)

Darunavir is a protease inhibitor, a class of drugs that blocks the protease enzyme HIV, preventing the virus from dividing and maturing. By interrupting this stage of the virus's life cycle, HIV, Darunavir reduces the amount of virus in the body and helps keep the viral load at undetectable levels. This medication is usually given in conjunction with a booster, such as ritonavir, to increase its effectiveness and bioavailability. Darunavir is known for its potency and is a common choice for patients who have resistance to other protease inhibitors.

In addition to its effectiveness in controlling viral load, Darunavir It is valued for its dosage flexibility, and can be administered once or twice a day, depending on the patient's needs.

Is there a cure or vaccine for HIV?

Currently, there is no definitive cure for HIV. Antiretroviral treatments (ARVs) are capable of suppressing virus replication, keeping the viral load at undetectable levels, but they do not eliminate the HIV completely from the organism. The HIV integrates its genetic material into the DNA of host cells, making it difficult to eradicate the virus. Research is underway to find a functional cure, where the virus is controlled without the need for ongoing treatment, or a sterilizing cure, where the virus is completely eliminated from the body. Promising approaches include gene therapies, the use of modified T cells, and strategies for reactivating and eliminating latent virus.

As for vaccines, the development of an effective vaccine against HIV has been a major challenge due to the high genetic variability of the virus and its ability to evade the immune system. Several studies and clinical trials are underway to find a preventive vaccine that can generate a robust and long-lasting immune response. Recently, there have been significant advances with vaccines based on viral vectors and recombinant proteins, but there is still no vaccine approved for general use. Research continues to be a global priority, with the goal of developing a vaccine that can help control or eradicate transmission of the HIV.

Although we do not yet have a cure or vaccine for HIV, advances in treatment and prevention have transformed the life prospects of people living with HIV. Antiretroviral therapy has made it possible to live with the virus in a controlled and healthy way, and preventive measures such as PrEP (Pre-Exposure Prophylaxis) and PEP (Post-Exposure Prophylaxis), have been effective in reducing transmission. Science is continually advancing, and with the joint efforts of researchers, health organizations and governments, there is hope that a cure or vaccine for HIV can be developed in the near future.

Advances with mRNA vaccines

Recent advances with mRNA vaccines have generated great expectations in the fight against HIV. This technology uses synthetic mRNA molecules to instruct the body's cells to produce specific viral proteins, stimulating an effective immune response. Since the approval of mRNA vaccines from Pfizer BioNTech e Modern, there has been significant progress in the efficacy and safety of these vaccines, as well as their ability to be rapidly adapted to combat new variants of the virus.

Currently, the Modern is conducting human clinical trials to test an mRNA vaccine against HIV. In partnership with the International Initiative for AIDS vaccine (IAVI) and other research institutes, the Modern is evaluating the safety and efficacy of the vaccine in 56 healthy volunteers. This study is a crucial part of the ongoing effort to develop an effective vaccine against HIV, using the same technology that was successful against COVID-19.

Continue to follow the showmetech and stay up to date with everything related to science and health. 

See also:

One in four Brazilians lost money in online scams, according to DataSenado/Nexus survey

Sources: Gov.BR, Agency Brazil e Gov.BR.

reviewed by Tiago Rodrigues in 06 / 12 / 2024